3.22
-0.92%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About TriSalus Life Sciences
From its filings with the US Securities and Exchange Commission
TriSalus Life Sciences is based in Westminster, Colorado and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker TLSI. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2025, it reported revenue of $45.2m and a net loss of $39.2m. At that date it held total assets of $35.3m and shareholders' equity of −$33.9m.
We are a growing, oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies, and with our investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 ("TRL9") agonist, for a range of different therapeutic and technology applications. Our ultimate goal is to transform the treatment paradigm for patients battling solid tumors. We have developed an innovative technology designed to overcome two of the most significant challenges that prevent optimal delivery and performance of therapeutics in these difficult-to-treat diseases: (i) high intratumoral pressure caused by tumor growth and collapsed vasculature restricting the delivery of oncology therapeutics and (ii) off target delivery. Nelitolimod, specifically, combined with our technology aims to address the immunosuppressive properties of tumor immune cells in liver, pancreas and other solid tumors. By systematically addressing these barriers, we aim to improve response to therapies and to enable improved patient outcomes.
Quoted from its 10-K, filed 5 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 18 Dec 2020
- Employees
- 102
- Website
- trisaluslifesci.com ↗
- Head office
- 6272 WEST 91ST AVENUE, WESTMINSTER, CO, 80031
- Incorporated in
- DE
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Mats WahlstromIndependent Non-Executive Chairman of the Board$243,750
- Ms. Mary SzelaPresident, Chief Executive Officer, Director, since 2023$4.1m
- Mr. David PatienceChief Financial Officer
- Mr. Dan GiordanoVice President - Finance
- Dr. Bryan CoxChief of Research
- Ms. Jodi DevlinChief of Clinical Operations$1.4m
- Dr. Richard MarshakChief Commercial Officer
- Ms. Jennifer StevensChief Regulatory Officer
- Dr. Arjun DesaiIndependent Director$151,250
- Dr. Gary GordonIndependent Director
- Mr. Kerry HicksIndependent Director$166,250
- Mr. David MatlinIndependent Director, since 2020$163,750
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Headquartered in Westminster, Colorado, with 102 employees.
- Operates in the Biotechnology sector within the Health Care industry.
- Owns FDA-cleared devices using Pressure-Enabled Drug Delivery (PEDD) technology.
Weaknesses
- Company went public via IPO in 2020-12-18.
- Relies on a single platform integrating drug delivery and immunotherapy.
- SD-101 is still in clinical stages as an investigational immunotherapeutic candidate.
Opportunities
- Expanding use of PEDD technology for liver and pancreatic tumor treatments.
- Potential to improve patient outcomes through SD-101 and PEDD integration.
- Growing interest in oncology treatments for liver and pancreatic tumors.
Threats
- Dependence on clinical trial success for SD-101 and PEDD applications.
- Competition in the oncology and biotechnology sectors.
- Regulatory challenges for FDA clearance of new applications.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.